dc.date.accessioned | 2019-07-04T17:00:23Z | |
dc.date.available | 2019-07-04T17:00:23Z | |
dc.date.created | 2019-07-04T17:00:23Z | |
dc.date.issued | 2019 | |
dc.identifier | https://hdl.handle.net/20.500.12866/6898 | |
dc.identifier | https://doi.org/10.1016/j.thromres.2019.05.006 | |
dc.description.abstract | OBJECTIVE: Specific protocols for anticoagulation for children on ECMO vary across institutions, with most using a continuous infusion of unfractionated heparin. The goal of this study is to aid clinician's decision on the best measure of heparin anticoagulation test; which would be the one that correlates well with heparin activity and helps in predicting hemorrhagic and thrombotic complications. DATA SOURCES: A comprehensive search of MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Scopus was conducted from each database's inception to 07/13/2018. STUDY SELECTION: Studies evaluating children (<18years) treated with ECMO and evaluating ACT, aPTT, TEG and Anti-Xa in any language were included. DATA EXTRACTION: Two reviewers selected and appraised studies independently, and abstracted data. RESULTS: We included 19 studies (759 patients, mean age 19.8months). Meta-analysis showed strong correlation between heparin dosing and anti-Xa. Additionally, there was not a strong correlation between laboratory tests and complications (hemorrhagic and thrombosis), or mortality. CONCLUSION: Based on current evidence, Anti-Xa is the only laboratory test that shows strong correlation with heparin infusion dose and seems like the most suitable test for monitoring of anticoagulation with heparin in children on ECMO. | |
dc.language | eng | |
dc.publisher | Elsevier | |
dc.relation | Thrombosis Research | |
dc.relation | 1879-2472 | |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | activated partial thromboplastin time | |
dc.subject | anticoagulation | |
dc.subject | Anticoagulation | |
dc.subject | bleeding | |
dc.subject | blood clotting factor 10a inhibitor | |
dc.subject | blood clotting test | |
dc.subject | child | |
dc.subject | Complications | |
dc.subject | Extracorporeal membrane oxygenation | |
dc.subject | extracorporeal oxygenation | |
dc.subject | heparin | |
dc.subject | human | |
dc.subject | Laboratory measures | |
dc.subject | major clinical study | |
dc.subject | meta analysis | |
dc.subject | mortality | |
dc.subject | Pediatrics | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | systematic review | |
dc.subject | thromboelastography | |
dc.subject | thrombosis | |
dc.title | Routine laboratory measures of heparin anticoagulation for children on extracorporeal membrane oxygenation: Systematic review and meta-analysis. | |
dc.type | info:eu-repo/semantics/article | |